The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid.

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

The following is a summary of “Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging ...

Researchers described a new skin disease in a male patient with erythroderma, causing 80 percent of his skin to be covered with red, exfoliating skin lesions that itched and burned. After undergoing ...

A significant number of Americans experience chronic inflammatory skin conditions with no pinpointed cause and often no ...

A new study from Huashan Hospital, Shanghai, provided strong evidence supporting the efficacy and safety of abrocitinib for ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to ...

US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U ...

More than 1,000,000 patients are being treated with Dupixent globally. 1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...